There is a keen research upon the effects of nutraceuticals on inflammatory bowel disease. The purpose of this study was to explore the effect of mastiha supplement, rich in bioactive nutraceuticals, in active inflammatory bowel disease. This is a randomised, double-blind, placebo-controlled clinical trial. Α total of 60 inflammatory bowel disease patients were enrolled and randomly allocated to mastiha (2.8 g/day) or placebo groups for 3 months adjunct to stable medical treatment. 
matory markers were assessed. A clinically important difference between groups in IBDQ was defined as primary outcome. Inflammatory Bowel Disease Questionnaire score significantly improved in verum compared with baseline (p = 0.004).
There was a significant decrease in faecal lysozyme in mastiha patients (p = 0.018) with the mean change being significant (p = 0.021), and significant increases of faecal lactoferrin (p = 0.001) and calprotectin (p = 0.029) in the placebo group. Fibrinogen reduced significantly (p = 0.006) with a significant mean change (p = 0.018), whereas iron increased (p = 0.032) in mastiha arm. Our results show regulation of faecal lysozyme by mastiha supplement adjunctive to pharmacological treatments in active inflammatory bowel disease. An effect secondary to a prebiotic potency is proposed.
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| INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease including Crohn's disease (CD) and ulcerative colitis (UC), which has turned into a global disease (Ng et al., 2017) . Lack of adherence to therapeutic regimens, suboptimal treatment and serious side effects, have increased the research interest in natural nutritional supplements rich in phytochemicals with antioxidant and anti-inflammatory properties that could be used for maintenance and recovery of intestinal functions.
Many natural products might be ineffective, because the necessity for the manufacturer to prove efficacy, safety, and quality of a marketed product is less strongly enforced than in the pharmaceutical sector due to lack of rigorous regulation (Andrew & Izzo, 2017; Hunter ClinicalTrials.gov Identifier: NCT02796339 & Hegele, 2017; Izzo, Hoon-Kim, Radhakrishnan, & Williamson, 2016) . Therefore, the research upon the efficacy of natural products must be based on mechanistic investigation, most importantly on formal clinical research studies (Minuz, Velo, Violi, & Ferro, 2017) .
Mastic or mastiha is the dried resinous exudate from stems and branches of Pistacia lentiscus (P. lentiscus L. var latifolius Coss or P. lentiscus var. Chia) according to European Pharmacopoeia monograph (01/2008:1876) . It is rich in terpenic acids with its main triterpenic acids, mastihadienonic, and isomastihadienonic, being absorbed and bioavailable in humans (Assimopoulou & Papageorgiou, 2005; Papada et al., 2018; Paraschos et al., 2007) . Additionally, it contains arabinogalactan-proteins (AGPs; Kottakis, Kouzi-Koliakou, Pendas, Kountouras, & Choli-Papadopoulou, 2009) , and some simple phenols have also been detected, however, in low concentrations or even in traces (Kaliora, Mylona, Chiou, Petsios, & Andrikopoulos, 2004) . Ancient Greek physicians (Hippocrates, Dioscorides, Galenos) reported for the first time the properties of mastiha and recommended its use for its therapeutic properties. Medical practitioners and botanists used mastiha for more than 2,500 years mainly for the treatment of stomach and intestine disorders such as gastralgia, dyspepsia, and peptic ulcer. Previous studies have documented its antioxidant (Dedoussis et al., 2004) and anti-inflammatory properties (Heo et al., 2006) , in addition to its beneficial effects on the gastrointestinal system. More specifically, in patients with gastric ulcers, who were supplemented only with mastiha at a dose of 2 g/day, symptoms resolved, whereas the treatment was confirmed endoscopically (Huwez & Al-Habbal, 1986) . Furthermore, Dabos, Sfika, Vlatta, and Giannikopoulos (2010) showed that mastiha is effective in improving symptoms of functional dyspepsia. A pilot study of safety on patients with established mild to moderately active CD suggested that a 4-week treatment with mastiha not only was safe but also significantly decreased the activity index, interleukin (IL)-6, and C-reactive protein (CRP) plasma levels. Additionally, mastiha might act as an immunomodulator on peripheral blood mononuclear cells, by inhibiting TNF-α and stimulating macrophage migration inhibitory factor (Kaliora, Stathopoulou, Triantafillidis, Dedoussis, & Andrikopoulos, 2007a, b) .
The European Medicines Agency has recognised mastiha as a herbal medicinal product with the following indications, (a) mild dyspeptic disorders and (b) symptomatic treatment of minor inflammations of the skin, and as an aid in healing of minor wounds (European Medicines Agency, 2015) .
This study is based on the necessity for novel treatments for IBD without serious side effects, the increasing interest in natural products with favorable effects on health and disease, and on previous research in mastiha. Thus, we aimed at demonstrating the effectiveness of this supplement in quality of life, clinical course, and inflammatory biomarkers of patients in mild to moderate relapse adjunct to current pharmacological IBD treatments.
| METHODS

| Ethics and trial registration
The study protocol was reviewed and approved by the Harokopio University Ethics Committee (49/29-10-2015) , and it was conducted according to the principles of the Declaration of Helsinki of 1975 as reflected in the approval by the Harokopio University Ethics Committee. Laboratory techniques were standardised, and the staff of the study was trained according to Good Clinical Practice. The trial was registered with ClinicalTrials.gov where the full trial protocol can be accessed (identifier: NCT02796339).
| Participants
Enrolment was stimulated through announcement to the Hellenic Society of CD and UC patients. Confirmed IBD patients, with endoscopy proven UC or CD, were enrolled based on certain inclusion and exclusion criteria (Table 1) . They were provided with detailed information regarding the aims, methods, anticipated benefits, and potential hazards of the study, and all patients received the patient information leaf- After the patient's consent was obtained, the contact who was independent of the recruitment process would allocate participants to intervention (verum or placebo). Randomisation was by a computergenerated random number list prepared by an investigator with no clinical involvement in the trial. Blinding was strictly maintained to intervention staff and participants. Except for the intervention staff, investigators and analysts were kept blind to intervention assignment of the participants. Staffs who obtained outcome measurements were not informed of the intervention group assignment. The mastiha group received natural mastiha supplement at a dose of 2.8 g daily (four tablets × 700-mg mastiha), whereas the placebo group received identical placebo tablets. This dose was chosen based on a recently published bioavailability study on healthy men, where an acute dose of 10 g of mastiha was well tolerated and no side effects were observed (Papada et al., 2018) . Preclinical data in 2,4,6-trinitrobenzene sulfonic acid colitic mice showed effectiveness in a daily dose of 100-mg/kg body weight (Gioxari et al., 2011) . Most importantly, a pilot study of Kaliora et al. (2007a, b) on patients with mild to moderate activity CD has served to identify and address any health and safety issues in mastiha supplementation in a daily dose above 2 g. No side effects or any discomfort was reported. The intervention lasted 3 months.
Both groups continued their usual medical treatment, which had to remain unaltered throughout the trial. Additionally, all patients received standard nutritional advice from dieticians and were encouraged to report any adverse effects experienced during the intervention. The verum tablets weighed 0.98 g/tablet and consisted of 70% crude resin, 14% microcrystalline cellulose, 14% dibasic calcium phosphate anhydrous, and 2% magnesium stearate. The resin was powdered prior to inclusion in tablet, and the powder obtained was off-white to yellowish. Similarly, the placebo tablets weighed 0.99 g/tablet and consisted of 49% microcrystalline cellulose with a characteristic off-white to yellowish color for similarity to verum, 49% dibasic calcium phosphate anhydrous, and 2% magnesium stea- (Guyatt et al., 1989) .
| Medical history
A medical history was recorded by a gastroenterologist, including general information (i.e., allergic reactions and smoking habits) as well as specific data regarding IBD (i.e., brief history of IBD, age of diagnosis, complications, and treatment). HBI was calculated for CD patients (Harvey & Bradshaw, 1980) , and PMS was calculated for UC patients (Lewis et al., 2008) .
| Blood and stool sample collection
Standard blood sampling (20 mL) was performed. After collection, blood samples were centrifuged at 3,000 rpm for 10 min at 4°C for plasma and serum isolation. All samples were stored at −80°C until further analysis. Additionally, patients provided stool samples using a stool preparation system filled with extraction buffer IDK Extract® (Immundiagnostik, AG). Stool extracts were kept for a maximum of 9 days at −20°C until further analysis.
| Αnthropometric assessment
Body weight was measured to the nearest 0.1 kg. Height was measured with a standard stadiometer to the nearest millimeter. Both measurements were performed twice. Body mass index was also calculated.
| Follow-up assessment
There was a biweekly telephone contact with the patients to check upon compliance and side effects. Compliance to treatments was evaluated by asking the patients to return a monthly diary completing the daily consumption of tablets. At the end of the intervention, all parameters of baseline assessment were re-evaluated.
2.6 | Laboratory analyses 2.6.1 | Evaluation of inflammation IL-6 (R&D Systems, Inc.) and IL-10 (OriGene Technologies, Inc.) were assessed applying sandwich ELISA at baseline and at follow-up. Additionally, CRP was measured in serum. Calprotectin, lysozyme, and lactoferrin were quantified in stool samples (Immundiagnostik, AG).
| Biochemical analyses
Iron (Fe), albumin, and plasma fibrinogen were quantified with an automatic biochemical analyser at baseline and at follow-up.
Routine laboratory tests included lactate dehydrogenase, serum urea measured to assess kidney safety, serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, γ-glutamyl transferase, alkaline phospatase, and total and direct bilirubin measured to assess liver safety. Serum amylase was measured to predict any pancreatic disorders.
| Sample size determination and statistical analysis
Sample size calculation was based on the findings of Irvine et al. (2000) . A sample size of 58 subjects, 29 per arm, is sufficient to detect a clinically important difference of 28.3 between groups in IBDQ score assuming an SD of 37.3 using a two-tailed t test of difference between means with 80% power and a 5% level of significance. Considering a dropout rate of 10%, the sample size required is 64 (32 per group).
Our primary outcome was a clinically significant improvement Table 3 describes routine biochemical data at baseline and at follow-up for mastiha and placebo. Also, serum Fe, albumin, and fibrinogen are presented. There were no significant differences at baseline between the two groups. At follow-up, only serum Fe was found to be significantly different between verum and placebo, with the verum experiencing increase. The mean change in plasma fibrinogen differed significantly between the two groups. More specifically, plasma fibrinogen decreased significantly only in the mastiha group at follow-up. Additionally, serum Fe increased significantly only in the verum group at follow-up, whereas serum glucose decreased significantly. Table 4 illustrates levels of inflammation markers in serum and in stools for the mastiha and placebo groups. The change in faecal lysozyme was significantly different between the two groups. Even when excluding patients who deviated from the protocol, lysozyme levels were found to be significantly different in the mastiha group after treatment (p = 0.027), the change between the two groups being significant after treatment (p = 0.036). Particularly, in UC patients, a significant difference in faecal lysozyme was reported at follow-up between these enrolled into the placebo and verum groups (p = 0.048). More specifically, there was a significant decrease only in the mastiha group at follow-up. IL-6 increased in both study groups.
Faecal calprotectin and lactoferrin increased significantly in the placebo group at follow-up, whereas in the verum group, they remained similar to baseline.
| DISCUSSION
Herein, we investigated the effect of a natural supplement prepared with mastiha to influence the clinical course of IBD. There are preclinical and clinical data supporting its safe administration in IBD (Gioxari et al., 2011; Kaliora et al., 2007a, b) , but this is the first study, according to our knowledge, evaluating the effectiveness of Mastiha on the basis of a phase-II randomised placebo-controlled clinical trial of both CD and UC patients in relapse. It is important to mention that no adverse effects were reported strengthening the safety profile of this natural product and coming into agreement with the results of other clinical studies that evaluated the effectiveness of mastiha in duodenal ulcer, dyspepsia, and hypercholesterolaemia with no adverse effects and excellent tolerability (Al-Habbal, Al-Habbal, & Huwez, 1984; Dabos et al., 2010; Kartalis et al., 2016) .
In order to assess our primary outcome, namely, improvement in quality of life, we used the IBDQ, the most widely used and validated tool (Alrubaiy, Rikaby, Dodds, Hutchings, & Williams, 2015) , which is fully validated in the Greek language as well as in the original English When evaluating disease severity, we observed a significant decrease in HBI at follow-up compared with baseline only in the mastiha group. However, the detected decrease should be interpreted with caution due to the subjective variables comprising the score (e.g., intensity of abdominal pain and general well-being). A longer period of treatment could possibly induce a further reduction in HBI and a significant mean change between groups, as well as a reduction in PMS for UC patients. However, the nature of active IBD with frequent changes in medical treatments and fluctuations in dosages would jeopardise the compliance with our inclusion and exclusion criteria.
To avoid patient discomfort as well as increased dropout rate and public health cost because of repeated endoscopies, we evaluated serum and faecal biomarkers of inflammation. No significant changes in CRP have been identified. Although CRP is widely used in clinical practice in order to assess and monitor disease activity and response to therapy, it has low specificity. Therefore, we evaluated also IL-6, a cytokine with pro-inflammatory effects, and IL-10, a cytokine with antiinflammatory activity. Even if we detected no significant changes in the mean changes between the two groups, further exploration of the effects of mastiha on other molecules of the inflammatory cascade is necessary. However, we detected noteworthy regulation in lysozyme, lactoferrin, and calprotectin levels. Previous research suggested that faecal lysozyme is increased in IBD patients and correlates with disease activity, especially in colonic IBD (van der Sluys Veer et al., 1998) . Our study showed a significant decrease in the lysozyme levels of the mastiha group. Most importantly, it showed a significant difference in mean change between the two groups. When analysing lysozyme in UC or CD individually, significantly lower levels at follow-up for the mastiha group in UC patients were reported. Lysozyme, an antimicrobial protein that regulates innate immune response, is expressed in both entities, CD and UC, mainly in small intestine but markedly also in the colon, as shown in both experimental animals (Coulombe et al., 2016) and humans (Fahlgren, Hammarström, Danielsson, & Hammarström, 2003; Rubio, 2011) . Because increased lysozyme expression is correlated with dysbiosis and with inflammation, herein, we could hypothesise that the effect of mastiha is rather a prebiotic one and possibly stronger in UC patients, related to the contained phenolic compounds and arabinogalactanes, both reported to have prebiotic activities (Dion, Chappuis, & Ripoll, 2016; Williamson & Clifford, 2017) . In addition, faecal calprotectin, a protein present in granulocytes and neutrophils, is released into the intestinal lumen after leucocyte epithelial migration into the inflamed gut mucosa and has good diagnostic accuracy in assessing mucosal healing in IBD patients. Furthermore, faecal lactoferrin is usually elevated in patients with active IBD detecting inflammation and correlates well with mucosal healing and histological improvement (Kochhar & Lashner, 2017) .
In our study, levels of calprotectin and lactoferrin significantly increased in the placebo but not in the mastiha group. Significantly lower levels of lactoferrin at follow-up were found in UC patients under mastiha treatment.
Regarding biochemical markers, fibrinogen is an acute phase reactant participating in thrombi formation, and its levels increase in inflammatory conditions. Increased fibrinogen levels are related with higher plasma viscosity and platelet activation, additionally to the microcirculation of the inflamed intestine (Hudson et al., 1996) . Higher levels of fibrinogen have been detected previously in IBD patients, and increasing levels were associated with disease activity (Dolapcioglu et al., 2014) . In our study, plasma fibrinogen levels decreased significantly in the mastiha group compared with baseline. Notably, the change in mean values between the two groups remained significant as well. A significant decrease of fibrinogen in the mastiha group at follow-up (250.2 ± 57.4 mg/dL) compared with baseline (288.3 ± 65.5 mg/dL, p = 0.022) was reported in CD but not in UC patients. These findings come into agreement with a study investigating the antidiabetic effects of two pentacyclic triterpenic acids, madecassid acid, and rotundic acid, on a mouse model. Apart from beneficial effects on oxidative and inflammatory stress, madecassic acid induced a significant reduction in fibrinogen levels and plasminogen activator inhibitor (Hsu, Hung, Hu, Lee, & Yin, 2015) . Furthermore, another protocol on a mouse model of diabetes showed that the triterpenoids asiatic and maslinic acids act as anticoagulants, by lowering fibrinogen levels among others (Hung, Yang, & Yin, 2015) . Even though these results refer to mouse models and should not be directly extrapolated to humans, we could hypothesise that terpenes in mastiha possibly exhibit favorable effects on homeostatic imbalance of IBD patients.
Serum Fe levels significantly increased in the mastiha group compared with baseline and compared with the follow-up levels in the placebo group. Additionally, serum Fe levels increased significantly in the mastiha group at follow-up (75.3 ± 32.2 μg/dl) compared with baseline (61.3 ± 30.7 μg/dl, p = 0.034) in CD but not in UC patients. Even though this increase could be partially attributed to increased food intake due to symptoms improvement, better nutrient absorption, or less intestinal losses, this finding should be interpreted with caution, because several nutrients may fluctuate in serum as positive or negative acute phase reactants as a part of inflammatory response (Forbes et al., 2017) .
The above findings could also point towards anti-inflammatory properties of the mastiha terpenes, which have been shown to be absorbed and bioavailable in the systemic circulation in healthy humans (Papada et al., 2018) .
Although this study reports interesting findings, it has some limitations, such as the absence of endoscopy at follow-up, precluding our ability to comment on any histological alterations. On the other hand, this limitation was compensated by the very tight control of the verum and placebo groups to ensure compliance of patients with the protocol, as well as the adequate number of participants that allowed for a power of 0.90 for the between-subjects main effect at an effect size of 0.37, a power of 0.95 for the within-subjects main effect at an effect size of 0.25, and a power of 0.95 for the interaction effect at an effect size of 0.25. Nevertheless, larger scale clinical trials are essential to determine the effect of terpene-rich mastiha in the health of patients with IBD and its potential underlying mechanisms.
| Conclusive remarks
Because there is an increasing usage of natural products among IBD patients, our study aimed at investigating the effects of mastiha in quality of life, disease activity, and biochemical and faecal inflammatory markers. Our results showed for the first time that a natural supplement prepared with mastiha could serve as an innovative treatment approach as an adjunct to conventional medical therapy. Mechanistically, regulation of faecal lysozyme secondary to a prebiotic effect is proposed.
